ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,975.38
0.00%
Dow Jones
42,706.56
0.00%
US Dollar vs MXN
20.3503
0.07%
Brent Oil
76.71
0.78%
Bitcoin
100,584.00
-1.66%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. iRhythm Technologies Inc (IRTC)

  7. iRhythm Technologies Inc (IRTC) Noticias

iRhythm Technologies Inc

iRhythm Technologies Inc (IRTC)

NASDAQ
92.30
1.48
(1.63%)
Cerrado 06 Enero 3:00PM
Delayed by 15 minutes
92.30
0.00
( 0.00% )
Pre Mercado: 7:29AM
Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

IRTC Noticias

Solo noticias oficiales

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
27 Diciembre 2024
IRTC (1.63%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
03 Diciembre 2024
IRTC (1.63%)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Edgar (US Regulatory)
12 Noviembre 2024
IRTC (1.63%)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Edgar (US Regulatory)
12 Noviembre 2024
IRTC (1.63%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
05 Noviembre 2024
IRTC (1.63%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
30 Octubre 2024
IRTC (1.63%)

Form 8-K - Current report
Edgar (US Regulatory)
30 Octubre 2024
IRTC (1.63%)

IRTC Discussion

Ver más
tw0122 tw0122 3 meses hace
Zio Services’ Clinically Proven Performance

The value of the Zio service has been demonstrated in over 100 original scientific research manuscripts5. Zio AT’s patient-centered design enables high patient compliance and analyzable time with minimal noise or artifact6-8, and real-world data shows an impressive 98% patient compliance9, in part thanks to Zio AT’s zero required patient manipulations. Furthermore, physicians agree with the Zio service's comprehensive end-of-wear report 99% of the time10-11.

About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all. To learn more about iRhythm, including its portfolio of Zio products and services, please visit irhythmtech.com.

Zio AT Indications For Use

The Zio AT device is intended to capture and transmit symptomatic and asymptomatic cardiac events and record continuous electrocardiogram (ECG) data for long-term monitoring. It is indicated for use on patients 18 years or older who may be asymptomatic or who may suffer from transient symptoms such as palpitations, shortness of breath, dizziness, light-headedness, pre-syncope, syncope, fatigue, or anxiety. It is not intended for use on critical care patients.
👍️0
jgrabar jgrabar 8 meses hace
Grabar Law Office is investigating whether the Board of Directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) ("iRhythm") breached their fiduciary duties to shareholders.

If you have held iRhythm shares since prior to January 11, 2022, learn more at https://grabarlaw.com/the-latest/irhythm-shareholder-investigation/, or call Joshua H. Grabar at 267-507-6085.
👍️0
ollik78 ollik78 3 años hace
Earnings today AH …
👍️0
BottomBounce BottomBounce 3 años hace
$IRTC has $122.47M in debt
👍️0
crudeoil24 crudeoil24 3 años hace
127.61 > hod.
👍️0
crudeoil24 crudeoil24 3 años hace
iRhythm shares are trading higher following the release of the 2022 Medicare Physician Fee Schedule Final Rule by the Centers for Medicare and Medicaid Services.
👍️0
crudeoil24 crudeoil24 3 años hace
iRhythm Technologies, Inc. is a digital healthcare company. It focuses on diagnosing cardiac arrhythmias by combining its wearable biosensing technology with cloud-based data analytics. It provides ambulatory electrocardiogram (ECG) monitoring for patients at risk for arrhythmias. It has created a portfolio of ambulatory cardiac monitoring services on a platform, called the Zio service. Its Zio service consists of wearable patch-based biosensors, Zio XT and Zio AT monitors, which records and stores ECG data from every patient heartbeat for up to 14 consecutive days. Zio service then provides cloud-based analysis of the recorded cardiac rhythms using its algorithms, an assessment review of the data by its cardiographic technicians, a report called Zio report, which includes the summary of findings and finally its cloud-based digital information system, ZioSuite, allows clinicians to connect via a Web browser or mobile application for online report interpretation and clinical workflows.
👍️0

Su Consulta Reciente

NASDAQ
IRTC
iRhythm Technologies
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados